FDA approves GE imaging agent

FDA approved PET imaging agent Vizamyl [18F]-flutemetamol from the GE Healthcare unit of General Electric Co. (NYSE:GE) for use in estimating beta amyloid neuritic plaque density in adults with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline. The company plans to launch the radioactive diagnostic in early 2014. GE Healthcare said Vizamyl will be "priced competitively" with other diagnostic imaging agents in the class. Eli Lilly and Co. (NYSE:LLY) markets PET imaging agent Amyvid florbetapir to estimate beta amyloid neuritic plaque density in patients with cognitive impairment who are being evaluated for AD and other causes of cognitive decline. ...